"Ductal carcinoma"

Management of Ductal Carcinoma in Situ of the Breast Guideline 1-10 Version 4 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Ontario Health (Cancer Care Ontario) Management of Ductal Carcinoma in Situ of the Breast M. Brackstone, LD Durocher-Allen, N. Califaretti, A. Eisen, S. Knowles, A. Koch, A. Salim, T. Plexman and the DCIS Expert Panel Report Date: March 31, 2024 Report Citation (Vancouver Style): Brackstone M, Durocher-Allen LD, Califaretti N, Eisen A, Knowles S, Koch A, Salim A, Plexman T, et al. Management of Ductal Carcinoma in Situ of the Breast. Toronto (ON): Ontario Health (Cancer Care Ontario); 2024, Mar 31. Program in Evidence-Based Care Guideline No.: 1-10 Version 4 Copyright This report is copyrighted by Ontario Health (Cancer Care Ontario

Imaging of Ductal Carcinoma in Situ (DCIS) New 2024 ACR Appropriateness Criteria® 1 Imaging of Ductal Carcinoma in Situ (DCIS) American College of Radiology ACR Appropriateness Criteria® Imaging of Ductal Carcinoma in Situ (DCIS) Variant 1: Adult. Newly diagnosed DCIS. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Digital breast tomosynthesis diagnostic Usually Not Appropriate ☢☢☢ Sestamibi MBI Usually Not Appropriate ☢☢☢ ACR Appropriateness Criteria® 2 Imaging of Ductal Carcinoma in Situ (DCIS) Variant 3: Adult. Evaluation for local recurrence in patient with history of breast conservation therapy for DCIS. Routine surveillance. Procedure Appropriateness Category Relative Radiation Level Digital breast tomosynthesis diagnostic Usually Appropriate ☢☢ Digital breast

ASTRO Guideline on Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ www.practicalradonc.orgChecking if the site connection is securewww.practicalradonc.org needs to review the security of your connection before proceeding.Ray ID: 8464e37fb9c271b4Performance & security by Cloudflare

Machine learning-based prediction of distant metastasis risk in invasive ductal carcinoma of the breast. More than 90% of deaths due to breast cancer (BC) are due to metastasis-related complications, with invasive ductal carcinoma (IDC) of the breast being the most common pathologic type of breast cancer and highly susceptible to metastasis to distant organs. BC patients who develop cancer

Clinical practice guidelines for ductal carcinoma in situ: Chinese society of breast surgery practice guidelines 2021.

Development and validation of a nomogram for predicting lymph node metastasis in ductal carcinoma in situ with microinvasion: A SEER population-based study. Ductal carcinoma in situ with microinvasion (DCIS-MI) is a special type of breast cancer. It is an invasive lesion less than 1.0 mm in size related to simple ductal carcinoma in situ (DCIS). Lymph node metastasis (LNM) in DCIS-MI often

Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study. To evaluate the long term risks of invasive breast cancer and death related to breast cancer after non-screen detected ductal carcinoma in situ. Risks for women in the general population and for women diagnosed with ductal carcinoma in situ via the screening programme were compared. Population based cohort study. Data from the National Disease Registration Service. All 27 543 women in England who were diagnosed with ductal carcinoma in situ, outside the NHS breast screening programme, during 1990 to 2018. Incident invasive breast cancer and death caused by breast cancer. By 31 December 2018, 3651 women with non-screen detected

Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. Ductal carcinoma in situ (DCIS) accounts for 15-25% of all breast cancer diagnoses. Its prognosis is excellent overall, the main risk being the occurrence of local breast events, as most cases of DCIS do not progress to invasive cancer. Systematic screening has greatly increased the incidence

Delving into female breast cancer: Distinct disease-specific survival outcomes between invasive lobular and ductal carcinomas revealed by propensity score matching. The difference in prognosis between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) is still controversial in the academic community. Resolving this controversy can help to more accurately determine patients

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown. To compare rates of invasive cancer in patients with low-risk DCIS receiving active

An MRI-Based Radiomics Nomogram to Distinguish Ductal Carcinoma In Situ with Microinvasion From Ductal Carcinoma In Situ of Breast Cancer. Accurate preoperative differentiation between ductal carcinoma in situ with microinvasion (DCISM) and ductal carcinoma in situ (DCIS) could facilitate treatment optimization and individualized risk assessment. The present study aims to build and validate

Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or Ductal Carcinoma In Situ in Patients Diagnosed with Flat Epithelial Atypia by Core Needle Biopsy (TBCRC 034). Flat epithelial atypia (FEA), a rare breast proliferative lesion, is often diagnosed following core biopsy (CB) of mammographic microcalcifications. In the prospective multi-institution TBCRC 034 trial, we investigate the upgrade rate to ductal carcinoma in situ (DCIS) or invasive cancer following excision for patients diagnosed with FEA on CB. Patients with a breast imaging reporting and data system (BI-RADS) ≤ 4 imaging abnormality and a concordant CB diagnosis of FEA were identified for excision. Upgrade rates were determined on the basis of local and central pathology review. The prespecified threshold

Impact of a 7-Gene Predictive Biosignature on Adjuvant Radiation Therapy Recommendations in Patients Undergoing Breast-Conserving Surgery for Ductal Carcinoma in Situ. Breast conservation therapy for patients with DCIS includes breast conserving surgery (BCS) with post-operative radiotherapy (RT). Because RT does not impact overall survival, identifying women who do not benefit from RT would

Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial. Intratumoral immunotherapy that leverages the biological characteristics of high-risk ductal carcinoma in situ (DCIS) may be able to reduce the extent of surgical treatment and provide an alternative approach to improve patient outcomes. To determine

The effect of neoadjuvant chemotherapy on ductal carcinoma in situ in triple-negative breast cancer patients: A nationwide analysis. Recent studies show that ductal carcinoma in situ (DCIS) accompanying HER2+ breast cancer can be completely eradicated following neoadjuvant systemic therapy in up to 52 %. We aimed to determine the complete response rate of DCIS in triple-negative breast cancer

MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial). Background Ductal carcinoma in situ (DCIS) is a nonlethal, preinvasive breast cancer for which breast MRI is best suited for accurate disease extent characterization. DCIS is often overtreated, necessitating robust models for improved risk stratification. Purpose

Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer. The literature contains different information about the prognosis of invasive lobular carcinoma of breast cancer (BC). We aimed to address the inconsistency

Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study. Management of low-risk ductal carcinoma in situ (DCIS) is controversial, with clinical trials currently assessing the safety of active monitoring amidst concern about overtreatment. Little is known about general community views regarding DCIS and its management. We aimed to explore women's

Racial disparities in disease-specific mortality and surgical management of patients with ductal carcinoma in situ with microinvasion. Given persistent racial disparities in breast cancer outcomes, this study explores racial differences in disease-specific mortality and surgical management among patients with microinvasive ductal carcinoma in situ (DCIS-MI). The Surveillance, Epidemiology

Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ. Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with highly variable clinical behavior, but risk stratification is still challenging. We sought to identify immune-related gene expression signatures of pure DCIS associated with different risks of breast